Mackie Research upgraded Cardiome Pharma (NASDAQ: CRME) from Hold to Spec. Buy with a price target of $2.80 (from $2.00).Analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE